Cytiva Increasing Manufacturing Capabilities In Parallel With COVID-19 R&D Surge
Emmanuel Ligner, president and CEO of Cytiva, talks to In Vivo about how the company will dramatically increase its manufacturing capabilities over the next five years, at a price tag of $500m.
You may also be interested in...
This episode of our weekly podcast covers Cognoa’s development of an app to detect autism spectrum disorder early, Novocure’s customer-focused business strategy during the pandemic, and the new $585m fund created by Longitude Capital to invest in medtech, pharma and biotech.
The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.
Signifier Medical Technologies is ramping up commercialization of its technology solutions for patients with snoring and sleep disordered breathing conditions.